
Aptuit hires chief executive from ICON
pharmafile | December 3, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Aptuit, ICON, goldman
Drug development services firm Aptuit has named Dr Jonathan Goldman as its chief executive, completing the company’s senior management leadership team.
Goldman will focus his efforts on the growth of Aptuit by establishing new partnerships with clients and pursuing strategic acquisitions. He joins the company from ICON Clinical Research, a global contract research organisation.
Goldman said: “I’m delighted to join Aptuit, and look forward to working closely with the entire team to leverage an outstanding value proposition that is unique in our industry.”
At ICON Goldman was most recently executive VP, Global Strategic and Business Development and a member of the senior leadership team. Previously, his roles at ICON included executive VP, Operations, Strategic Programs and chief medical officer, ICON Medical Imaging.
Before joining ICON Goldman served for seven years as the chief medical officer of POINT Biomedical, a US-based biopharma company that discovered and developed microsphere technologies and drugs.
Aptuit’s chairman Timothy Tyson said: “We’re enthusiastic that Jonathan is joining us. He brings exceptional experience in science, sales and medicine, along with the innate talents that are needed to advance us to the next level of growth and accomplishments.”
Related Content

Cloud on the horizon: Cloud computing and the clinical trial
Originally published in the September edition of Pharmafocus, Matt Fellows investigates how cloud computing may …

AMRI buys two Aptuit facilities
Contract research and manufacturing firm AMRI has acquired two businesses from pharmaceutical services company Aptuit …

Icon to acquire Aptiv Solutions
Icon has acquired US clinical trial specialists Aptiv Solutions for $143.5 million as it looks …






